Please login to the form below

Not currently logged in

RPS criticises homeopathic treatments

The UK's Royal Pharmaceutical Society has criticised the marketing of homeopathic treatments in a response to a consultation from the MHRA

The UK's Royal Pharmaceutical Society (RPS) has criticised the marketing of homeopathic treatments in a response to a consultation from the Medicines and Healthcare products Regulatory Agency (MHRA).

The RPS said it 'expressed concerns that the public may not fully understand the principles on which homeopathy is based' with more regulation needed in terms of what information is provided on product labels.

Current rules allow labels to display claims based on the product's traditional homeopathic use, with the RPS recommending that these labels carry a statement that these efficacy claims are not based on the same requirements applied to conventional drugs.

Chief scientific advisor with the RPS, Jayne Lawrence, said: "Given the lack of clinical and scientific evidence to support homeopathy, the RPSGB does not endorse homeopathy as a form of treatment.

"The Society strongly believes that any advertising for any homeopathic product, regardless of its licensing status needs to include the statements that there is no scientific evidence for homeopathy nor any evidence to support the clinical efficacy of homeopathic products beyond a placebo effect."

Of particular concern was the use of the word 'medicine' in relation to homeopathy, with the RPS claiming this could be viewed by patients as legitimising homeopathic products as clinically approved treatments.

Confusion between homeopathic products and herbal remedies was also discussed, with the RPS requesting the MHRA make the difference between the two products clear to the public so a fully informed choice can be made.

4th November 2010


Featured jobs

Subscribe to our email news alerts


Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...